Background & Objective: Although data on the effects of liraglutide and semaglutide in
patients with diabetes have been reviewed, their therapeutic outcomes in obese/overweight …

Purpose The effect and safety of Semaglutide and Liraglutide on weight loss in people with
obesity or overweight were evaluated by a Network Meta-Analysis system to provide an …

Introduction: Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is a class of
hypoglycemic medications. Semaglutide once-weekly (QW) and liraglutide once-daily (OD) …

Aims SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent
semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in …

Background Obesity is a major public health issue, and new pharmaceuticals for weight
management are needed. Therefore, we evaluated the efficacy and safety of the glucagon …

Importance Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like
peptide-1 analogues available for weight management. Objective To compare the efficacy …

Objective Higher doses of the glucagon‐like peptide‐1 agonists liraglutide and, more
recently, semaglutide have demonstrated a significant reduction in body weight. However …

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for
chronic weight management provides a novel effective strategy against obesity. The reliable …

Objective: We systematically assessed the efficacy of liraglutide in non-diabetic obese
adults. Methods: Six databases were searched up to July 2021 for randomized controlled …

OBJECTIVE To investigate the efficacy and safety of once-daily semaglutide in comparison
with once-daily liraglutide and placebo in patients with type 2 diabetes. RESEARCH …